XML 186 R75.htm IDEA: XBRL DOCUMENT v3.22.2
Share-based Payments and Non-Convertible Equity Certificates (Tables)
 12 Months Ended
Mar. 31, 2022
Share-Based Payments [Abstract]  
Disclosure of Movement in the Share-Based Payment Liability The movement in the share-based payment liability during the period is reflected below:
(EUR thousand)
SBP2021
Opening balance as of April 17,396 
Valuation up to August 27974 
SBP value as of August 278,370 
Expense recognized in the profit and loss upon capital reorganization58,744 
SBP value as of August 2867,114 
Cash settlements upon reorganization(29,333)
Conversion upon reorganization of remaining SBP liability to equity at FV(37,781)
Closing balance as of March 31, 2021— 
Disclosure of Movement in the NC-PECs Liability
The movement in the NC-PECs liability is reflected below:
(EUR thousand)For the financial year ended March 31
NC-PECs20212020
Nominal value including accrued interest on NC-PECs issued at the beginning of the year1,920 1,750 
Mark-to-market fair value charge(138)— 
Accrued interests on NC-PECs79 (5)
Transfer to equity(1,861)— 
Reclassifications— 175 
Total value of NC-PECs direct investment— 1,920 
Value at the beginning of the year2,971 2,744 
Accrued interest120 227 
Derecognition of residual amount to profit and loss(101)— 
Transfer to equity(2,990)— 
Reclassifications— — 
Interest bearing obligations towards senior management of Global Blue Group— 2,971 
Total value of NC-PECs including accrued interest— 4,891 
(Thousand of units)For the financial year ended March 31
NC-PECs20212020
NC-PECs issued at the beginning of the year927 927 
Issuance of NC-PECs— — 
Transfer of NC-PECs to equity(927)— 
Number of NC-PECs issued— 927 
Disclosure of Number and Weighted Average Exercise Prices of Outstanding Share Options Four tranches of options vesting on four respective vesting dates have been granted. Within each respective tranche, there are a further four tranches of options with four different exercise prices, as below:
Share options granted (thousands)Mar 5, 2022Sep 5, 2022Sep 5, 2023Sep 5, 2024Total
US$8.50971 324 647 647 2,589 
US$10.50822 274 548 548 2,192 
US$12.50673 224 448 448 1,793 
US$14.50523 175 349 349 1,396 
Total2,989 997 1,992 1,992 7,970 
The following table shows the SOPs granted and outstanding at the beginning and end of the reporting period:
For the financial year ended March 31
20222021
Average exercise price per share option (USD)Number of options (thousands)Average exercise price per share option (USD)Number of options (thousands)
As of April 110.98 8,457 — — 
Granted during the year— — 10.98 8,457 
Forfeited during the year10.98 (477)— — 
As of March 3110.98 7,980 10.98 8,457 
Vested and exercisable of March 3111.00 2,925 — — 
Disclosure of Range of Exercise Prices of Outstanding Share Options Share options outstanding at the end of the year have the following expiry dates and exercise prices:
Share options outstanding (thousands)For the financial year ended March 31
Grant dateExpiry dateExercise price (USD)20222021
June 25, 2019June 23, 202710.59 461 487 
November 12, 2020August 15, 20268.50 2,443 2,589 
November 12, 2020August 15, 202610.50 2,068 2,192 
November 12, 2020August 15, 202612.50 1,692 1,793 
November 12, 2020August 15, 202614.50 1,316 1,396 
Total7,980 8,457 
Weighted average remaining contractual life of options outstanding at the end of the period4.4 years5.4 years
Disclosure of Indirect Measurement of Fair Value of Share Options Granted During Period
The fair value was calculated using a binomial option pricing model. The model inputs were:
2019 SOP2020 SOP
Fair value at grant date (USD)1.03 0.57 0.20 0.06 0.01 
Share price at grant date (USD)10.59 10.34 10.34 10.34 10.34 
Exercise price (USD)10.59 8.50 10.50 12.50 14.50 
Expected volatility25 %50 %50 %50 %50 %
Risk free interest rate1.91 %0.50 %0.50 %0.50 %0.50 %
Disclosure of Number and Weighted Average Exercise Prices of Outstanding Restricted Shares
The following table shows the RSAs granted and outstanding at the beginning and end of the reporting period:
Number of shares (thousands)For the financial year ended March 31
20222021
As of April 1475 — 
Granted during the year1,426 475 
Vested during the year(93)— 
Forfeited during the year(134)— 
As of March 311,674 475 
Weighted average fair value (USD)6.62 8.65
Disclosure of Indirect Measurement of Fair Value of Restricted Shares Granted During Period The model inputs were the share price at grant date and the risk free interest rate as stipulated in the table below. No dividend payments were considered in the fair value.
Grant dateNov 12, 2020Nov 12, 2020Nov 12, 2020Oct 12, 2021Oct 12, 2021Oct 12, 2021Oct 12, 2021Oct 12, 2021Oct 12, 2021
Vesting dateSep 5, 2022Sep 5, 2023Sep 5, 2024Sep 5, 2022Sep 5, 2023Sep 5, 2024Sep 5, 2025Sep 5, 2022Sep 5, 2023
Share price at grant date (USD)10.34 10.34 10.34 6.60 6.60 6.60 6.60 6.60 6.60 
Risk free interest rate0.16 %0.22 %0.30 %0.10 %0.21 %0.40 %0.62 %0.10 %0.21 %
Fair value per share (USD)8.65 8.65 8.65 5.48 5.48 5.48 5.48 6.60 6.60